Massachusetts General Hospital

About This Center

Multiple Myeloma Treatment Program

The Center for Multiple Myeloma provides comprehensive treatment for all stages of multiple myeloma and a condition called MGUS, or monoclonal gammopathy of undetermined significance. MGUS can progress to become multiple myeloma. We also treat patients with related plasma cell disorders, including:

  • Multiple myeloma
  • Smoldering multiple myeloma
  • Monoclonal gammopathy of unknown significance
  • Waldenstrom’s macroglobulinemia
  • Amyloidosis
  • Light chain deposition disease
  • Other rare conditions

We tailor treatment to each individual patient. Each member of our multidisciplinary care team has special expertise in treating this particular kind of cancer.

Innovative Approaches

The Center for Multiple Myeloma provides comprehensive clinical care in a compassionate and caring environment. Our patients receive:

  • The latest treatments and access to cutting-edge research, clinical trials, and novel targeted therapies
  • Access to the Bone Marrow Transplant Program, where autologous and allogenic stem cell transplants are performed

Schedule an Appointment

Myeloma Clinical Trials

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT).

Learn more about this trial


A Study of two investigational drugs including PVX-410 (a Multi-Peptide Cancer Vaccine), and Citarinostat (a Histone Deacetylase Inhibitor (HDAC)) +/- Lenalidomide for Patients with Moderate or High Risk of Progression Smoldering Multiple Myeloma

This phase 1 research study is evaluating an immunotherapy as a possible treatment for moderate/high risk Smoldering Multiple Myeloma. The following investigational treatments will be involved in this study: PVX-410, Citarinostat (CC-96241) and Lenalidomide (Revlimid).

Learn more about this trial


Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Learn more about this trial


Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.

Learn more about this trial


Myeloma-Developing Regimens Using Genomics (MyDRUG)

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms.

Learn more about this trial


MMRF Molecular Profiling Protocol

The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.

Learn more about this trial


Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying Daratumumab as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).

Learn more about this trial


A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Dabrafenib and trametinib have been used in the treatment for other cancers in other research studies, and information from those research studies suggest that these agents may help to kill multiple myeloma cells. Dabrafenib and trametinib, which are investigated in this research study may or may not kill myeloma cells effectively. We would like to see if these drugs given alone or in combination safely and effectively kill these cancer cells.

Learn more about this trial


A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

The purpose of this trial is to evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA.

Learn more about this trial


A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is a Phase II clinical trial. This study will assess the safety and tolerability of denosumab in Multiple Myeloma participants, by studying drug interactions with different parts of the body.

Learn more about this trial


A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

Learn more about this trial



AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma

This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia.

Learn more about this trial


ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma

It is possible that the combination of lenalidomide, dexamethasone and ACE 011 may reduce or prevent the growth of cancer cells along with improving anemia and bone lesions that sometimes occur in people with multiple myeloma.

Learn more about this trial


A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected hematological malignancies who have relapsed after, or are refractory to prior standard therapy, and for whom there is no standard salvage regimen available.

Learn more about this trial


Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

This research study is studying a combination of drugs as a possible treatment for multiple myeloma. The drugs that will be administered are: - ABI-009 (nab-rapamycin) - Pomalidomide - Dexamethasone.

Learn more about this trial


Study of bb21217 in Multiple Myeloma

Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb21217). Following manufacture of the drug product, subjects will receive lymphodepletion prior to bb21217 infusion.

Learn more about this trial


Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease.

Learn more about this trial


Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Antibody, In Relapse/ Refractory Multiple Myeloma

The purpose of this trial is to assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Learn more about this trial


MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.

Learn more about this trial

Center Information

55 Fruit Street
Boston, MA 02114

Find a Specialist

Create your account today and get matched to myeloma treatment centers and specialists around the US.

  • Find centers with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;